Advertisement
INCY or LLY or REGN
Which Stock Would AI Choose? Incyte Corporation (INCY) vs. Eli Lilly and Company (LLY) vs. Regeneron Pharmaceuticals (REGN) Stock Comparison
Key Takeaways
- INCY delivered robust Q4 2025 revenue growth of 28% driven by Jakafi and Opzelura, but shares faced pressure amid valuation concerns and recent share price weakness.
- LLY reported explosive Q4 revenue of $19.29 billion fueled by obesity drugs Mounjaro and Zepbound, positioning it for 41% earnings growth in 2026 despite elevated valuations.
- REGN showed stable performance with Q4 revenue at $3.88 billion, bolstered by Dupixent expansions and positive obesity trial data, trading at attractive multiples.
- Year-to-date, LLY leads with +7.7% returns, followed by REGN at +1.44% and INCY down -2.87%, reflecting divergent momentum in biotech.
- INCY offers the lowest forward P/E at 12.41, contrasting LLY's premium 28.90 amid growth trade-offs.
- All three exhibit low betas under 1.0, signaling reduced volatility relative to broader markets.
Introduction
This comparison examines INCY, LLY, and REGN, three biopharmaceutical leaders navigating oncology, immunology, and metabolic therapies in a dynamic market. Investors seeking exposure to innovative pipelines and revenue diversification will find value here, as recent earnings highlight shifts from legacy blockbusters toward next-generation assets. Traders monitoring relative performance amid sector rotations can assess momentum, valuations, and catalysts for short- to medium-term positioning in this high-stakes biotech arena.
INCY Overview and Recent Performance
Incyte Corporation (INCY) focuses on small-molecule therapeutics for oncology, hematology, and inflammation, with flagship products like Jakafi for myelofibrosis and Opzelura for dermatology. In recent market activity, shares traded around $95.94, reflecting a market cap of $19.1 billion and a forward P/E of 12.41. Q4 2025 revenue surged 28% to $1.51 billion, driven by strong Jakafi and Opzelura sales, underscoring a pivot from single-product reliance to pipeline expansion. Sentiment has softened due to share price weakness over recent weeks, with analysts noting mixed fair value signals and competition pressures, though robust cash flows ahead of key conferences support stability.
LLY Overview and Recent Performance
Eli Lilly and Company (LLY) develops pharmaceuticals across cardiometabolic, oncology, and immunology, powered by blockbusters Mounjaro and Zepbound for diabetes and obesity. Trading near $990 with an $886 billion market cap and forward P/E of 28.90, the stock reflects premium growth expectations. Recent quarters showed Q4 revenue of $19.29 billion, propelled by soaring demand for weight-loss therapies. Performance has included pullbacks amid pricing concerns and competition, yet expansions like Amazon Pharmacy access for Zepbound and 41.1% projected 2026 earnings growth have buoyed sentiment in volatile conditions.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) specializes in monoclonal antibodies for eye diseases, allergies, and cancer, featuring Eylea and Dupixent. Shares hover at $759.86, with an $80.3 billion market cap and forward P/E of 17.70. Q4 revenue reached $3.88 billion, supported by immunology expansions. Recent activity shows mixed returns, with modest 30-day gains offset by weekly dips, as biosimilar pressures on Eylea weigh on sentiment. Positive Phase 3 data for obesity candidate olatorepatide and Dupixent approvals signal pipeline strength, positioning REGN favorably amid undervaluation debates.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the platform's top AI-powered trading bots from hundreds available, each scanning thousands of tickers for real-time opportunities using technical and fundamental analyses. Only those excelling in current volatility—such as low-drawdown strategies in energy, semiconductors, and industrials—earn a spot, with stats like annualized returns up to 215%, win rates from 53% to 95%, and profit factors highlighting consistency. These bots vary in styles from 5-minute scalps to swing trades across 1-25 tickers, including leveraged ETFs. Explore Trending AI Robots to identify patterns suited to today’s market dynamics.
Head-to-Head Comparison
INCY, LLY, and REGN operate in overlapping biotech realms but diverge in scale and drivers: INCY's small-molecule focus yields efficient valuations (P/E 15 TTM) but exposes it to Jakafi patent risks by 2028, contrasting LLY's diversified pharma model with obesity dominance fueling hyper-growth at a premium (P/E 43 TTM). REGN balances antibody innovation with partnerships like Sanofi, offering mid-tier stability (P/E 18 TTM) amid Eylea biosimilars. Momentum favors LLY's catalysts, while risks include competition for all; low betas (0.4-0.84) indicate resilience, with INCY most sensitive to valuation shifts.
Tickeron AI Verdict
Tickeron’s AI leans toward LLY based on superior trend consistency from obesity tailwinds and projected earnings acceleration, outweighing its richer valuation relative to INCY and REGN. REGN ranks close for pipeline catalysts and relative undervaluation, while INCY trails on momentum. Observable factors suggest higher probability of outperformance for LLY in prevailing conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s), and REGN’s FA Score reflects 1 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- LLY’s FA Score: 2 green, 3 red.
- REGN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 5 TA indicator(s) are bullish while LLY’s TA Score has 4 bullish TA indicator(s), and REGN’s TA Score reflects 2 bullish TA indicator(s).
- INCY’s TA Score: 5 bullish, 4 bearish.
- LLY’s TA Score: 4 bullish, 3 bearish.
- REGN’s TA Score: 2 bullish, 6 bearish.
Price Growth
INCY (@Biotechnology) experienced а +1.82% price change this week, while LLY (@Pharmaceuticals: Major) price change was -1.32% , and REGN (@Biotechnology) price fluctuated +0.23% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
Reported Earning Dates
INCY is expected to report earnings on Apr 28, 2026.
LLY is expected to report earnings on Apr 30, 2026.
REGN is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| INCY | LLY | REGN | |
| Capitalization | 19.5B | 828B | 79.4B |
| EBITDA | 1.76B | 31.7B | 5.82B |
| Gain YTD | -0.962 | -13.595 | -2.643 |
| P/E Ratio | 15.26 | 40.39 | 18.09 |
| Revenue | 5.14B | 65.2B | 14.3B |
| Total Cash | 3.58B | 7.27B | 8.61B |
| Total Debt | 40.4M | 42.5B | 2.71B |
INCY | LLY | REGN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 62 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 62 Fair valued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 72 | 20 | 75 | |
SMR RATING 1..100 | 32 | 13 | 54 | |
PRICE GROWTH RATING 1..100 | 49 | 55 | 47 | |
P/E GROWTH RATING 1..100 | 100 | 94 | 40 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for LLY (62) in the Pharmaceuticals Major industry, and is significantly better than the same rating for INCY (69) in the Biotechnology industry. This means that REGN's stock grew somewhat faster than LLY’s and significantly faster than INCY’s over the last 12 months.
LLY's Profit vs Risk Rating (20) in the Pharmaceuticals Major industry is somewhat better than the same rating for INCY (72) in the Biotechnology industry, and is somewhat better than the same rating for REGN (75) in the Biotechnology industry. This means that LLY's stock grew somewhat faster than INCY’s and somewhat faster than REGN’s over the last 12 months.
LLY's SMR Rating (13) in the Pharmaceuticals Major industry is in the same range as INCY (32) in the Biotechnology industry, and is somewhat better than the same rating for REGN (54) in the Biotechnology industry. This means that LLY's stock grew similarly to INCY’s and somewhat faster than REGN’s over the last 12 months.
REGN's Price Growth Rating (47) in the Biotechnology industry is in the same range as INCY (49) in the Biotechnology industry, and is in the same range as LLY (55) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to INCY’s and similarly to LLY’s over the last 12 months.
REGN's P/E Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for LLY (94) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for INCY (100) in the Biotechnology industry. This means that REGN's stock grew somewhat faster than LLY’s and somewhat faster than INCY’s over the last 12 months.
| INCY | LLY | REGN | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | 2 days ago 74% | N/A |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 70% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 61% | 2 days ago 52% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 67% | 2 days ago 49% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 59% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 57% | 2 days ago 60% |
| Advances ODDS (%) | 10 days ago 61% | 10 days ago 71% | 18 days ago 64% |
| Declines ODDS (%) | 3 days ago 60% | 3 days ago 55% | 3 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 67% | N/A | 2 days ago 49% |
| Aroon ODDS (%) | 2 days ago 60% | 2 days ago 57% | 2 days ago 70% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NACP | 53.32 | 0.58 | +1.11% |
| Impact Shares NAACP Minority Empwrmt ETF | |||
| JIVE | 91.33 | 0.86 | +0.95% |
| JPMorgan International Value ETF | |||
| TBFC | 29.06 | 0.17 | +0.60% |
| The Brinsmere Fund - Conservative ETF | |||
| XUDV | 29.51 | 0.05 | +0.18% |
| Franklin U.S. Dividend Mltplr Idx ETF | |||
| BRKU | 21.24 | -0.10 | -0.45% |
| Direxion Daily BRKB Bull 2X Shares | |||
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with AZN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then AZN could also see price increases.